Inozyme Pharma, Inc.
INZYDelisted Jul 1, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001693011
Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in Inozyme Pharma, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 39
- −8 vs. Q2 2022
- Shares held
- 30.8M
- −711.2K (−2.3%) vs. Q2 2022
- Total value
- $82.7M
- −$66.7M (−44.7%) vs. Q2 2022
- New holders
- 2
- 11 more added
- Sold out
- 10
- 15 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INZY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 87 | $202.3M |
| Q1 2025 | 97 | $42.5M |
| Q4 2024 | 105 | $145.1M |
| Q3 2024 | 89 | $285.5M |
| Q2 2024 | 90 | $240.1M |
| Q1 2024 | 89 | $382.0M |
| Q4 2023 | 80 | $213.3M |
| Q3 2023 | 77 | $204.6M |
| Q2 2023 | 74 | $190.3M |
| Q1 2023 | 50 | $183.4M |
| Q4 2022 | 37 | $30.4M |
| Q3 2022 | 39 | $82.7M |
| Q2 2022 | 47 | $149.4M |
| Q1 2022 | 50 | $71.2M |
| Q4 2021 | 51 | $118.2M |
| Q3 2021 | 52 | $202.7M |
| Q2 2021 | 50 | $337.1M |
| Q1 2021 | 55 | $379.4M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Inozyme Pharma, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 3,655,308 | $9.80M | 0.62% | 00.0% | Unchanged |
| Deep Track Capital, LP | 3,250,000 | $8.71M | 0.43% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 2,807,618 | $7.52M | 0.19% | +167,562+6.3% | Added |
| VR Adviser, LLC | 2,709,987 | $7.26M | 1.12% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 2,661,154 | $7.13M | 2.61% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 2,596,672 | $6.96M | 0.02% | +50,000+2.0% | Added |
| NEA Management Company, LLC | 2,444,379 | $6.55M | 0.33% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 2,090,436 | $5.60M | 0.11% | −605,936−22.5% | Reduced |
| CHI Advisors LLC | 1,996,277 | $5.35M | 1.44% | −37,525−1.8% | Reduced |
| Vanguard Group Inc | 1,343,063 | $3.60M | 0.00% | −11,153−0.8% | Reduced |
| Sphera Funds Management Ltd. | 1,175,058 | $3.15M | 0.56% | +9,458+0.8% | Added |
| Janus Henderson Group PLC | 705,577 | $1.91M | 0.00% | −224,379−24.1% | Reduced |
| MPM Oncology Impact Management LP | 661,144 | $1.77M | 0.42% | −3,836−0.6% | Reduced |
| FMR LLC | 609,380 | $1.63M | 0.00% | −439−0.1% | Reduced |
| BlackRock Inc. | 428,431 | $1.15M | 0.00% | −2,089−0.5% | Reduced |
| Laurion Capital Management LP | 271,800 | $728.0K | 0.02% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 233,685 | $626.0K | 0.00% | +16,760+7.7% | Added |
| Millennium Management LLC | 170,184 | $456.0K | 0.00% | −2,908−1.7% | Reduced |
| UBS Oconnor LLC | 165,498 | $444.0K | 0.01% | −5,849−3.4% | Reduced |
| Renaissance Technologies LLC | 155,400 | $416.0K | 0.00% | +37,100+31.4% | Added |
| Bridgeway Capital Management, LLC | 133,400 | $358.0K | 0.01% | +46,000+52.6% | Added |
| Walleye Capital LLC | 117,529 | $315.0K | 0.01% | +16,087+15.9% | Added |
| Citadel Advisors LLC | 110,648 | $297.0K | 0.00% | −10,179−8.4% | Reduced |
| State Street Corp | 76,355 | $205.0K | 0.00% | +27,300+55.7% | Added |
| Overbrook Management Corp | 69,326 | $186.0K | 0.05% | 00.0% | Unchanged |
| State of Wisconsin Investment Board | 48,800 | $131.0K | 0.00% | −20,100−29.2% | Reduced |
| Northern Trust Corp | 40,304 | $108.0K | 0.00% | −6,686−14.2% | Reduced |
| Dimensional Fund Advisors LP | 27,043 | $73.0K | 0.00% | +13,956+106.6% | Added |
| Morgan Stanley | 22,284 | $59.0K | 0.00% | −18,890−45.9% | Reduced |
| Bank of New York Mellon Corp | 20,243 | $54.0K | 0.00% | −1,655−7.6% | Reduced |
| Charles Schwab Investment Management Inc | 16,549 | $45.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 13,183 | $35.0K | 0.00% | +13,183 | New |
| Barclays PLC | 6,403 | $17.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 2,927 | $8.00K | 0.00% | +2,920+41,714.3% | Added |
| Federated Hermes, Inc. | 1,533 | $4.00K | 0.00% | +1,533 | New |
| Royal Bank of Canada | 690 | $2.00K | 0.00% | +221+47.1% | Added |
| Wells Fargo & Company | 157 | $0 | 0.00% | −20−11.3% | Reduced |
| Crewe Advisors LLC | 163 | $0 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 60 | $0 | 0.00% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 0 | $0 | 0.00% | −106,999−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −25,649−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −12,505−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −11,179−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −4,800−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −117−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −143−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −115−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −76−100.0% | Sold out |